Oxford develops rapid diagnostic test to detect Covid-19 within 5mins
Oxford University claimed that scientists from its Physics department have developed an extremely rapid diagnostic test for Covid-19. The rapid diagnostic test can detect and ... Read More
Regeneron bags Inmazeb FDA approval for treatment of Ebola
Inmazeb FDA approval : Regeneron Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its antibody cocktail Inmazeb (atoltivimab, maftivimab, and ... Read More
AstraZeneca to advance AZD7442 into phase 3 Covid-19 trials
AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is ... Read More
IBRANCE fails to meet primary endpoint in early breast cancer trial
Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage ... Read More
VirTrial to help BetterLife Pharma in launching COVID-19 clinical trials
VirTrial, a US bioscience technology company, has been selected by Canadian biotech company BetterLife Pharma as its telehealth platform provider of choice for launching COVID-19 clinical trials. ... Read More
BMS’ Zeposia succeeds in True North clinical trial in ulcerative colitis
Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis ... Read More
R3 Vascular raises $17.8m for devices to treat peripheral artery diseases
R3 Vascular, an early-stage US medical device company, has raised $17.8 million in a Series A financing round, led by an undisclosed corporate investor and 415 ... Read More
Apellis reports positive results for pegcetacoplan in phase 2 C3G trial
Apellis Pharmaceuticals has reported positive results for pegcetacoplan from the phase 2 DISCOVERY clinical trial in patients with C3 glomerulopathy (C3G), a type of kidney ... Read More
EC strikes deal for supply of JNJ-78436735 Covid-19 vaccine candidate
Johnson & Johnson (J&J) said that the European Commission (EC) has approved an advance purchase agreement for securing 200 million doses of the JNJ-78436735 Covid-19 ... Read More
Noxopharm doses first patient in NOXCOVID-1 clinical trial with Veyonda
Australian drug development company Noxopharm has dosed the first patient in the phase 1 NOXCOVID-1 clinical trial with Veyonda, its lead pipeline candidate, in hospitalized ... Read More